Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Myelodysplastic Syndromes 9Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Neuroblastoma 5Lymphoma, Non-Hodgkin 5Leukemia 5Rhabdoid Tumor 3Neoplasms, Plasma Cell 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Hodgkin Disease 3Wilms Tumor 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Medulloblastoma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Biphenotypic, Acute 2Graft vs Host Disease 2Ganglioneuroblastoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Recurrence 1

Interventions

Cell Count 2Stem Cell Transplantation 1Specimen Handling 1Polymerase Chain Reaction 1Flow Cytometry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cytomegalovirus Infections × Stem Cell Transplantation × Clear all
NCT05589844 2023-04-27

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Roswell Park Cancer Institute

Phase 1 Withdrawn

Cytomegalovirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡